Bernhard Wunsch
Overview
Explore the profile of Bernhard Wunsch including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
274
Citations
1081
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Thale I, Nass E, Vinnenberg L, Todesca L, Budde T, Maisuls I, et al.
Pharmaceutics
. 2025 Feb;
17(2).
PMID: 40006521
: The Ca-activated K channel K3.1 is not only involved in physiological processes such as immune reactions and control of vascular tone, but is highly expressed in various tumor entities....
2.
Deuther-Conrad W, Schepmann D, Iriepa I, Lopez-Munoz F, Chioua M, Wunsch B, et al.
Int J Mol Sci
. 2025 Feb;
26(3).
PMID: 39941036
Sigma receptors (σRs) represent very attractive biological targets for the development of potential agents for the treatment of several neurological disorders. In the search for new small molecule drugs against...
3.
Stereoselective Synthesis and Biological Evaluation of Perhydroquinoxaline-Based κ Receptor Agonists
Hoffmann J, Schepmann D, Daniliuc C, Bermudez M, Wunsch B
Int J Mol Sci
. 2025 Feb;
26(3).
PMID: 39940767
The hydroxylated perhydroquinoxaline was designed by conformational restriction of the prototypical κ receptor agonist U-50,488 and the introduction of an additional polar group. The synthesis of comprised ten reaction steps...
4.
Kroger L, Borgert S, Lauwers M, Steinkruger M, Jose J, Pietsch M, et al.
Molecules
. 2025 Jan;
30(1.
PMID: 39795120
The serine/threonine kinase CK2 (formerly known as casein kinase II) plays a crucial role in various CNS disorders and is highly expressed in various types of cancer. Therefore, inhibiting this...
5.
Rumler H, Schmithals C, Werner C, Bollacke A, Aichele D, Gotz C, et al.
ACS Pharmacol Transl Sci
. 2024 Dec;
7(12):3846-3866.
PMID: 39698287
The human protein kinase CK2 is a promising target for cancer treatment. Only two CK2 inhibitors have reached clinical trials until today. Among others, a dibenzofuran scaffold has emerged as...
6.
Winge T, Schepmann D, Schmidt J, Wunsch B
Eur J Med Chem
. 2024 Nov;
281:117002.
PMID: 39547080
The σ receptor plays a key role in the regulation of various processes in the human body; it is involved in the development of neurodegenerative and neuropsychiatric diseases and is...
7.
Luken J, Goerges G, Schreiber J, Schmidt J, Frehland B, Schepmann D, et al.
J Med Chem
. 2024 Oct;
67(21):19678-19688.
PMID: 39418125
Administration of negative allosteric modulators of GluN2B subunit-containing NMDA receptors such as Ro 25-6981 () and ifenprodil () results in neuroprotective effects. In this study, the phenol of and was...
8.
Costanzo G, Cosentino G, Pasquinucci L, Amata E, Schepmann D, Wunsch B
ChemMedChem
. 2024 Sep;
19(24):e202400596.
PMID: 39236252
Enantiomerically pure 4-hydroxymorphan-7-ones were prepared in two steps from the natural product (R)-carvone. At first, the isopropenyl moiety of (R)-carvone was converted into the epoxide 7. A Domino reaction consisting...
9.
Dombovski A, Steigerwald R, Ritter N, Disse P, Goerges G, Osthues J, et al.
J Pharm Anal
. 2024 Aug;
14(7):100945.
PMID: 39104865
Image 1.
10.
Rathing F, Schepmann D, Wunsch B
Arch Pharm (Weinheim)
. 2024 Jun;
357(9):e2400279.
PMID: 38889396
Cyclopenta[g]quinolones of type 4 were designed with the aim to bioisosterically replace the phenol of potent GluN2B ligands such as ifenprodil and Ro 25-6981 by the quinolone system and to...